Latest stories on AGIO
Agios Pharmaceuticals, Inc. (AGIO) Discusses Global License Agreement for Cevidoplenib and Strategic Expansion in Rare Hematology Transcript
Seeking Alpha58 · neutralproduct/pr
Agios: 'Sell' On Tebapivat Setback LR-MDS And Competitive PK Activator Drug Class
Seeking Alpha22 · bearishanalyst
Agios Extends Mitapivat into Pediatric Thalassemia, Opening a New Long-Term Growth Path
TipRanks67 · bullishproduct/pr
Agios Advances Pediatric Mitapivat Trial in Transfusion-Dependent Thalassemia: What Investors Should Watch
TipRanks58 · neutralproduct/pr
Agios to discontinue candidate for myelodysplastic syndromes
Seeking Alpha33 · bearishproduct/pr
Agios Provides Update on Phase 2b Trial of Tebapivat in Lower-Risk Myelodysplastic Syndromes | AGIO Stock News
StockTitan33 · bearishproduct/pr
Agios’ PYRUKYND® (mitapivat) Approved in the European Union for Adults with Thalassemia | AGIO Stock News
StockTitan77 · bullishproduct/pr